Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Oncogene

• Publication date

  2001-03-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.onc.1204222PMID 11313888
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway

  2000cited by this paper
• Role of HER2 gene overexpression in breast carcinoma

  2000cited by this paper
• Determination of Her-2/Neu Status in Breast Carcinoma: Comparative Analysis of Immunohistochemistry and Fluorescent In Situ Hybridization

  2000cited by this paper
• Genes implicated in hereditary breast cancer syndromes.

  2000cited by this paper
• DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis

  1999cited by this paper
• Benign salivary gland neoplasms.

  1999cited by this paper
• Malignant salivary gland neoplasms.

  1999cited by this paper
• Morphological features of the minor salivary glands.

  1999cited by this paper
• Genetic alterations in ERBB2-amplified breast carcinomas.

  1999cited by this paper
• Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress

  1999cited by this paper
• p53 and cyclinX D1 protein expression in carcinomas of the parotid gland.

  1998cited by this paper
• ErbB Receptors and EGF-like Ligands: Cell Lineage Determination and Oncogenesis Through Combinatorial Signaling

  1997cited by this paper
• Bcl-2 and Bax function independently to regulate cell death

  1997cited by this paper
• 14-3-3sigma is a p53-regulated inhibitor of G2/M progression.

  1997cited by this paper
• p53 Mediates Permanent Arrest over Multiple Cell Cycles in Response to γ-Irradiation

  1997cited by this paper
• A model for p53-induced apoptosis

  1997cited by this paper
• Natriuretic peptide immunoreactivity in nerve structures and Purkinje fibres of human, pig and sheep hearts

  1997cited by this paper
• ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

  1997cited by this paper
• Li-Fraumeni syndrome--a molecular and clinical review.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• 14-3-3σ Is a p53-Regulated Inhibitor of G2/M Progression

  1997cited by this paper
• p53 and ATM: cell cycle, cell death, and cancer.

  1997cited by this paper
• Genetic instability in animal tumorigenesis models.

  1997cited by this paper
• Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours

  1996cited by this paper
• Transgenic approaches to salivary gland research.

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• ErbB2 activation and signal transduction in normal and malignant mammary cells

  1996cited by this paper
• A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

  1996cited by this paper
• Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations*

  1996cited by this paper
• Different roles for cyclins D1 and E in regulation of the G1-to-S transition

  1995cited by this paper
• Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death

  1995cited by this paper
• Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research

  1995cited by this paper
• Radiation-induced cell cycle arrest compromised by p21 deficiency

  1995cited by this paper
• Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.

  1994cited by this paper
• c-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis.

  1994cited by this paper
• E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions.

  1994cited by this paper
• Tumor spectrum analysis in p53-mutant mice.

  1994cited by this paper
• Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.

  1994cited by this paper
• Genetic background alters the spectrum of tumors that develop in p53‐deficient mice

  1993cited by this paper
• p53 mutations increase resistance to ionizing radiation.

  1993cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice.

  1992cited by this paper
• p53 function and dysfunction.

  1992cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992influential reference
• Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.

  1992cited by this paper
• Transgenic oncogene mice. Tumor phenotype predicts genotype.

  1991cited by this paper
• Cooperation between oncogenes.

  1991cited by this paper
• The c‐erbB‐2 proto‐oncogene in human pancreatic cancer

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene.

  1989cited by this paper
• Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

  1988influential reference
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

  1986cited by this paper
• Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

  1981cited by this paper

• p53/MDM2 signaling pathway in aging, senescence and tumorigenesis.

  2024cites this paper
• Genetically engineered mouse models of head and neck cancers

  2023cites this paper
• Tumorigenesis

  2020cites this paper
• High expression of Livin serves as a predictive indicator for parotid gland tumors.

  2019cites this paper
• Cooperation Between Pten and Smad4 in Murine Salivary Gland Tumor Formation and Progression

  2018cites this paper
• p53 is not expressed in Indian salivary gland neoplasm: A light microscopic and immunohistiochemical retrospective review of 140 salivary gland neoplasms.

  2012cites this paper
• Target-Selected ENU Mutagenesis to Develop Cancer Models in the Rat

  2012cites this paper
• Rhabdomyosarcomas in Aging A/J Mice

  2011cites this paper
• Trisomy chromosome 5 is a recurrent cytogenetic lesion in mammary tumors from parous MMTV-erbB-2 transgenic mice.

  2011cites this paper
• Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53

  2010cites this paper
• Biological and Oncogenic Properties of p53-Deficient Salivary Gland Epithelial Cells with Particular Emphasis on Stromal-Epithelial Interactions in Tumorigenesis

  2007cites this paper
• Spontaneous and Irradiation-Induced Tumor Susceptibility in Brca2 Germline Mutant Mice and Cooperative Effects with a p53 Germline Mutation

  2006cites this paper
• P53 levels determine outcome during β-catenin tumor initiation and metastasis in the mammary gland and male germ cells

  2006cites this paper
• Guilt by association? p53 and the development of aneuploidy in cancer.

  2005cites this paper
• Immunological Prevention of a Multigene Cancer Syndrome

  2004cites this paper
• HER 2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER 2-Transgenic Mice

  2004cites this paper
• HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice

  2004cites this paper
• Normal lymphocyte development and thymic lymphoma formation in Brca1 exon-11-deficient mice

  2003influential citation
• PyV-mT-induced parotid gland hyperplasia as detected by altered lectin reactivity is not modulated by inducible nitric oxide deficiency.

  2003cites this paper
• Squamous cell carcinoma and mammary abscess formation through squamous metaplasia in Smad4/Dpc4 conditional knockout mice

  2003cites this paper
• Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.

  2003cites this paper
• Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer.

  2002cites this paper
• The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors.

  2002cites this paper
• Tumor formation in Brca1 conditional mutant mice

  2002influential citation
• Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

  2001cites this paper
• BRCA1-associated tumorigenesis: what have we learned from knockout mice?

  2001cites this paper
• Knockout mouse models and mammary tumorigenesis.

  2001cites this paper
• Oncotargets and Therapy Dovepress Immunocompromised and Immunocompetent Mouse Models for Head and Neck Squamous Cell Carcinoma Xin-hua Liang Ya-ling Tang

  year unknowncites this paper